Femasys (NASDAQ:FEMY) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Femasys (NASDAQ:FEMY) posted its quarterly earnings results on Friday. The company reported ($1.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02), Zacks reports. The business had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.73 million. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.

Femasys Stock Performance

FEMY opened at $2.29 on Friday. The stock has a market capitalization of $6.92 million, a price-to-earnings ratio of -0.65 and a beta of -2.08. The company has a quick ratio of 1.98, a current ratio of 3.91 and a debt-to-equity ratio of 0.53. Femasys has a twelve month low of $2.19 and a twelve month high of $22.20. The company has a 50-day simple moving average of $3.59 and a 200 day simple moving average of $7.31.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Weiss Ratings upgraded Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Maxim Group cut their price target on Femasys to $10.00 and set a “buy” rating for the company in a report on Friday. Finally, Wall Street Zen upgraded shares of Femasys to a “hold” rating in a report on Saturday, June 13th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $56.67.

Insider Activity at Femasys

In other news, CFO Dov Elefant purchased 15,625 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was bought at an average price of $3.20 per share, with a total value of $50,000.00. Following the acquisition, the chief financial officer owned 15,625 shares in the company, valued at approximately $50,000. The trade was a ? increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Kathy Lee-Sepsick acquired 15,625 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the chief executive officer directly owned 15,625 shares of the company’s stock, valued at $50,000. The trade was a ? increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 38,750 shares of company stock valued at $124,000 over the last 90 days. Corporate insiders own 7.75% of the company’s stock.

Institutional Investors Weigh In On Femasys

Several hedge funds and other institutional investors have recently made changes to their positions in FEMY. Banco BTG Pactual S.A. acquired a new stake in Femasys in the fourth quarter valued at approximately $88,000. Geode Capital Management LLC boosted its stake in shares of Femasys by 50.8% during the fourth quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock valued at $224,000 after purchasing an additional 131,052 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Femasys in the fourth quarter valued at approximately $62,000. Cetera Investment Advisers bought a new position in Femasys in the 4th quarter valued at approximately $36,000. Finally, HRT Financial LP acquired a new position in Femasys in the 4th quarter valued at approximately $30,000. 65.27% of the stock is owned by institutional investors.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.